MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

Phase 1/2 Completed 73 enrolled Menarini Group Medpace, Inc. · collab Theradex · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).

Timeline

Start: 2017-03-10
Primary completion: 2023-04-13
Completion: 2023-04-13

Publications

Martinelli G, Solomon SR, Mukherjee S, Santoro A, Strickland SA, Vives S, Ravandi F, Walter RB, Cook RJ, Lech-Maranda E, Calbacho M, Wierzbowska A, Marconi G, Acuna-Cruz E, Cano-Ferri I, Bertolini F, Rzymski T, Paoli A, Merlo GM, Auriol FK, Zicari S, Galleu A, Gupta I, Montesinos P. Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. Blood Neoplasia. 2025 Oct 24;3(1):100178. doi: 10.1016/j.bneo.2025.100178. eCollection 2026 Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dapolsertib	Small molecule	25 mg	Oral
Subject	dapolsertib	Small molecule	50 mg	Oral
Subject	dapolsertib	Small molecule	75 mg	Oral
Subject	dapolsertib	Small molecule	100 mg	Oral
Subject	dapolsertib	Small molecule	125 mg	Oral
Subject	dapolsertib	Small molecule	150 mg	Oral

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications